Tandem Diabetes Care (LTS:0M0F) Tariff Resilience Score: 7/10 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0M0F Tandem Diabetes Care Inc LTS:0M0F
68 GF Score
Price $15.64
GF Value $29.80
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Tariff Resilience Score?

Tandem Diabetes Care LTS:0M0F +0.58% 68 Tariff Resilience Score is 7 as of Jul. 16, 2026. GuruFocus rates LTS:0M0F with a GF Score™ of 68/100 and a GF Value™ of $29.80 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 834 Medical Devices & Instruments companies, Tandem Diabetes Care ranks better than 98.08% on this metric.

Tandem Diabetes Care has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Tandem Diabetes Care has Tandem Diabetes Care's medical devices are subject to some tariff risks, but its U.S.-centric market and potential for tariff exemptions in healthcare provide moderate resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Tandem Diabetes Care might have Highly Resilient.

Tandem Diabetes Care  (LTS:0M0F) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Tandem Diabetes Care Tariff Resilience Score Related Terms

LTS:0M0F vs CNMD, AORT, LMRI: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Tandem Diabetes Care's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tandem Diabetes Care Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Tariff Resilience Score falls into.


LTS:0M0F
68GF Score
Tandem Diabetes Care Inc LTS:0M0F
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Tandem Diabetes Care (LTS:0M0F) has a Tariff Resilience Score of 7 as of Jul. 16, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Tandem Diabetes Care ranks #16 out of 834 companies in the Medical Devices & Instruments industry, placing it in the top 1.9%.
Is Tandem Diabetes Care's Tariff Resilience Score too high?
Tandem Diabetes Care's current Tariff Resilience Score is 7. Based on the distribution chart, Tandem Diabetes Care ranks #16 out of 834 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tandem Diabetes Care has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Tariff Resilience Score compare to CNMD and AORT?
According to the Medical Devices & Instruments industry distribution chart, Tandem Diabetes Care ranks #16 out of 834 companies for Tariff Resilience Score. This places Tandem Diabetes Care in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Tandem Diabetes Care's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.80, compared to a current price of $15.64 — trading 47.5% below its estimated fair value. The current Tariff Resilience Score is 7. Tandem Diabetes Care's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Tariff Resilience Score is 7 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of $15.64 is trading 47.5% below its estimated GF Value™ of $29.80. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for LTS:0M0F:

  • Tariff Resilience Score: 7
  • GF Value™: $29.80 vs. price of $15.64 (47.5% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tandem Diabetes Care Business Description

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
68GF Score

Get the complete analysis for LTS:0M0F

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.64
Price
$29.80
GF Value